Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBaylor Scott & White Part B Policy Update | OpenPa…
    Ask Trek AI about this page
    CurrentBaylor Scott & White Health PlanPolicy 307

    Step Therapy Policy - Medicare Part B

    Customize your policy alerts

    Sign up for Baylor Scott & White Health Plan Policy 307 alerts

    Get alerted when Policy 307 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs step therapy for Medicare Part B outpatient drugs and certain devices. Non-preferred products generally require a new start, failure or intolerance/contraindication to applicable preferred alternatives, and applicable CMS or Plan criteria.

    Policy Summary
    PayerBaylor Scott & White Health Plan
    PolicyStep Therapy Policy - Medicare Part B
    Policy CodePolicy 307
    Change TypeUpdated
    Effective DateOct 1, 2026
    Last ReviewSep 24, 2026
    Next Review DateSep 24, 2027
    Key ActionBefore coverage of a non-preferred drug or device, address use of preferred alternatives for the specific indication.
    SourceLink
    POLICY UPDATE CHANGES

    The policy added bendamustine, bone antiresorptive therapy, and taxane classes.

    Cimerli was removed from the preferred list because commercialization was paused.

    Sickle cell gene therapy policy references and Pavblu were added, and step therapy was clarified to apply to all preferred drugs.

    The policy added a non-muscle-invasive bladder cancer treatment class and denosumab biosimilars to bone antiresorptive therapy.

    Denosumab biosimilars were removed for Prolia and added for Xgeva, and an anti-emetic class was added.

    The methotrexate class was removed.

    The infliximab class was updated to include specific drug agents, and Vykoura was added to the leucovorin class.

    365 daysNew-start lookback
    AllPreferred alternatives requiring trial or exception

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3 classes
    Product classifications
    DexcomPreferred continuous glucose monitor
    ParityUnlisted Part B drug coverage

    Coverage Criteria

    Non-preferred medication

    Non-preferred medications are medically necessary when all of the following are met.

    Non-preferred medication criteria

    • New start: The member has not received the requested medication during the past 365 days.365 days
    • Preferred alternatives addressed: The member has failed an adequate trial of, or has clinically significant intolerance or a contraindication to, all preferred drugs that can also be used for the requested indication.All applicable preferred drugs
    • Additional coverage criteria: The member meets additional clinical coverage criteria under the applicable CMS or Plan policy.Applicable CMS or BSWHP policy

      Apply the applicable CMS coverage policy first; when no applicable Medicare coverage policy exists, apply the referenced BSWHP policy.

    Non-preferred device

    Non-preferred devices are medically necessary when all of the following are met.

    Non-preferred device criteria

    • Clinical rationale: The provider submits clinical rationale explaining why the non-preferred device is medically necessary and why preferred agents are not appropriate.Required
    • Additional coverage criteria: The member meets additional clinical coverage criteria specified in the applicable table.Applicable CMS or BSWHP policy

      For continuous glucose monitors, apply LCD 33822, Glucose Monitors.

    Unlisted Medicare Part B drugs

    Other Medicare outpatient Part B drugs not listed in the table are covered at parity.

    Unlisted Part B drugs: All other Medicare outpatient Part B drugs not listed are covered at parity and are not subject to the preferred/non-preferred step.

    Apply the applicable BSWHP medical policy or cancer chemotherapy/therapy guideline.

    Referenced Coding

    Referenced LCDHCPCS
    33822Glucose Monitors

    Provider Requirements

    Prior Authorization

    Prior Authorization Requirements

    See the specific drug or device policy for the applicable prior authorization requirements before requesting coverage under this step therapy policy.

    Step Therapy

    Preferred Alternative Required First

    Before requesting a non-preferred drug or device for a specific indication, address use of the applicable preferred therapeutic alternative. Preferred and non-preferred products are evaluated for cost and clinical appropriateness, and the preferred alternative must be considered before the non-preferred product can be covered.

    • Document the indication and the applicable preferred alternative(s).
    • For continuous glucose monitors, Dexcom is preferred; all other CGMs are non-preferred.

    Policy Background

    Step therapy requires the provider to use or address a preferred therapeutic alternative before coverage of a non-preferred drug or device for a specific indication. Preferred and non-preferred products are evaluated for cost and clinical appropriateness; the Plan considers requiring preferred products first clinically reasonable based on relevant literature and compendia. Applicable CMS coverage policies are applied first, followed by the applicable Baylor Scott & White Health Plan policy when no Medicare coverage policy exists, and then the supplemental step therapy requirements.

    Key Definitions

    Step therapy
    DefinitionA trial of a preferred therapeutic alternative required before coverage of a non-preferred drug or device for a specific indication.
    New start
    DefinitionA member who has not received the requested medication during the preceding 365 days.
    Product classifications
    Class 1Preferred product.
    Class 2Non-preferred product.
    Class 3

    Initial Therapy

    Non-preferred medication initial therapy

    Initial coverage of a non-preferred medication requires all applicable step therapy criteria.

    • New start: The member has not received the requested medication during the past 365 days.365 days
    • Preferred alternatives addressed: The member has failed an adequate trial of, or has clinically significant intolerance or a contraindication to, all preferred drugs that can also be used for the requested indication.All applicable preferred drugs
    • Additional coverage criteria: The member meets additional clinical coverage criteria under the applicable CMS or Plan policy.

    Step Therapy Requirements

    RuleRequirementApplicable criteria
    1Use or address preferred therapeutic alternatives before coverage of a non-preferred drug or device for the specific indication.The member must meet applicable CMS or Baylor Scott & White Health Plan criteria.
    RuleOrder of applicationRequirement
    2Apply the relevant CMS coverage policy first. If no applicable Medicare coverage policy exists, apply the referenced Baylor Scott & White Health Plan policy.After the applicable CMS or Plan policy is applied, apply the supplemental step therapy requirement.
    Preferred alternativesNon-preferred agentsRequirement
    Aprepitant and generic anti-emetics: granisetron, metoclopramide, ondansetron, prochlorperazine, palonosetron, and BelrapzoAkynzeo and CinvantiFor oncology regimens, address the preferred alternatives before coverage of a non-preferred agent and meet BSWHP policy 219 criteria.
    Aprepitant and generic anti-emeticsVarubiFor oncology regimens, address the preferred alternatives before coverage of a non-preferred agent.
    Class or indicationPreferred product(s)Non-preferred product(s)Applicable policy
    EGFR inhibitors for colorectal cancersErbituxVectibixBSWHP policy 219
    Gene therapies for sickle cell diseaseCasgevyExagamglogene autotemcel and lovotibeglogene autotemcel (Lyfgenia)BSWHP policies 310 and 311
    InfliximabInfliximab (unbranded) and RemicadeAvsola and InflectraBSWHP policy 215
    IrinotecanConventional irinotecan, generic and CamptosarLiposomal irinotecan (Onivyde)BSWHP policy 219
    LeucovorinFusilev and leucovorinKhapzory and VykouraBSWHP policy 215 or 219
    Long-acting G-CSFUdenyca and NeulastaFulphila, Fylnetra, Nyvepria, Stimufend, Ziextenzo, and other long-acting G-CSF agentsBSWHP policy 215 or 219
    PD-1 inhibitors for bladder cancer treatmentsLoqtorziKeytrudaBSWHP policy 219
    Pemetrexed for cancerGeneric or brand pemetrexed (Alimta) and other pemetrexed 505(b)(2) productsOpdivo, Axtle, Pemfexy, and Pemrydi RTUBSWHP policy 219
    RituximabRuxience and TruximaRiabni, Rituxan, and Rituxan HycelaBSWHP policy 215
    Short-acting G-CSFZarxioNeupogen, Nivestym, Releuko, and other short-acting G-CSF agentsBSWHP policy 215 or 219
    Taxane/docetaxel formulationsTaxotere and HerzumaPaclitaxel protein-bound (Abraxane), other paclitaxel protein-bound 505(b)(2) formulations, Herceptin, and Herceptin HylectaBSWHP policy 219
    Trop-2 directed antibodyTrodelvyDatrowayBSWHP policy 219
    VEGF inhibitors for ophthalmic indicationsAvastinBeovu and ByoovizBSWHP policy 215
    Device classPreferred deviceNon-preferred devicesRequirement
    Continuous glucose monitorsDexcomAll other continuous glucose monitorsSubmit clinical rationale explaining why the non-preferred device is medically necessary and why Dexcom is not appropriate; meet LCD 33822 (Glucose Monitors) criteria.

    Biosimilar and Related Product Guidance

    Billing Rule

    Bone antiresorptive therapy: verify preferred status

    In the bone antiresorptive therapy class, Avastin biosimilars—including Vegzelma, Aukelso, Bomyntra, Bilprevda, Osenvelt, Wyost, and Xbryk—and Xgeva are listed as non-preferred. Apply BSWHP policy 219 for applicable coverage criteria.

    • Preferred-to-non-preferred status is indication- and class-specific.
    Billing Rule

    Infliximab: address preferred therapy first

    For the infliximab class, Avsola and Inflectra are non-preferred alternatives to unbranded infliximab or Remicade. Apply BSWHP policy 215 and document the required preferred-alternative step therapy before requesting a non-preferred product.

    Policy Summary
    PayerBaylor Scott & White Health Plan
    PolicyStep Therapy Policy - Medicare Part B
    Policy CodePolicy 307
    Change TypeUpdated
    Effective DateOct 1, 2026
    Last ReviewSep 24, 2026
    Next Review DateSep 24, 2027
    Key ActionBefore coverage of a non-preferred drug or device, address use of preferred alternatives for the specific indication.
    SourceLink
    On This Page
    Coverage CriteriaReferenced CodingProvider RequirementsPolicy BackgroundKey DefinitionsInitial TherapyStep Therapy RequirementsBiosimilar and Related Product Guidance
    Documentation Required

    Non-Preferred Device Rationale

    For a non-preferred device, submit clinical rationale explaining why the device is medically necessary and why the preferred agent or device is not appropriate for the member.

    • For continuous glucose monitors, document why a CGM other than preferred Dexcom is necessary.
    • Apply the additional clinical coverage criteria in the applicable CMS or Baylor Scott & White Health Plan policy, including LCD 33822 for glucose monitors.
    Documentation Required

    Preferred-Drug Trial Documentation

    For a non-preferred medication, document that the member is a new start and has not received the requested medication during the past 365 days. Also document failure of an adequate trial, clinically significant intolerance, or a contraindication to all preferred drugs that can be used for the requested indication.

    • Document the additional clinical coverage criteria required by CMS or the applicable Plan policy.
    • For oncology anti-emetics, apply BSWHP Policy 219, Cancer Chemotherapy / Therapy Guidelines.
    • For other Medicare outpatient Part B drugs not listed in the policy, apply BSWHP Policy 215 or Policy 219 as applicable; preferred and non-preferred agents are covered at parity when no step applies.
    Denial Risk

    Failure to Satisfy Step Therapy Criteria

    Coverage for a non-preferred medication or device may be denied when the applicable step therapy requirements are not satisfied. The requested product must meet the member’s coverage document and all applicable CMS or Plan policy criteria.

    • Medication: denial may result if the member is not a new start, has not failed an adequate trial of or experienced clinically significant intolerance or contraindication to all applicable preferred drugs, or does not meet additional clinical criteria.
    • Device: denial may result if clinical rationale for medical necessity and the inappropriateness of preferred options is not submitted, or if additional clinical criteria are not met.
    Applicable CMS or Baylor Scott & White Health Plan policy.
    Applicable CMS or BSWHP policy

    Non-preferred device initial therapy

    Initial coverage of a non-preferred device requires provider rationale and all applicable additional criteria.

    • Clinical rationale: The provider submits clinical rationale explaining why the non-preferred device is medically necessary and why preferred agents are not appropriate.Required
    • Additional coverage criteria: The member meets additional clinical coverage criteria specified in the applicable table.LCD 33822 for continuous glucose monitors
    Billing Rule

    Long-acting G-CSF: verify preferred status

    For long-acting G-CSF therapy, Udenyca and Neulasta are preferred; Fulphila, Fylnetra, Nyvepria, Stimufend, Ziextenzo, and other long-acting G-CSF agents are non-preferred. Apply BSWHP policy 215 or policy 219, as applicable.

    Billing Rule

    Herceptin: apply taxane-class step therapy

    In the taxane/docetaxel class, Herzuma is listed as preferred, while Herceptin and Herceptin Hylecta are listed as non-preferred. Apply BSWHP policy 219 and document the required preferred-alternative criteria for a non-preferred request.

    Billing Rule

    Ophthalmic VEGF inhibitors: verify preferred status

    For ophthalmic indications, Avastin is listed as preferred and Byooviz is listed as non-preferred. Apply BSWHP policy 215 and document the required criteria when requesting a non-preferred ophthalmic VEGF inhibitor.